We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.74B
AUM Growth
+$339M
Cap. Flow
-$310M
Cap. Flow %
-11.3%
Top 10 Hldgs %
45.15%
Holding
404
New
120
Increased
93
Reduced
80
Closed
88

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$23.4M
2
XOM icon
ExxonMobil
XOM
+$15.3M
3
PXD
Pioneer Natural Resource Co.
PXD
+$12.1M
4
MRK icon
Merck
MRK
+$9.03M
5
BPMC
Blueprint Medicines
BPMC
+$8.62M

Top Sells

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$53.9M
2
AGN
Allergan plc
AGN
+$33.8M
3
IWM icon
iShares Russell 2000 ETF
IWM
+$24.7M
4
MBLY
Mobileye N.V.
MBLY
+$7.21M
5
MNKD icon
MannKind Corp
MNKD
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 8.27%
2 Energy 1.27%
3 Technology 0.21%
4 Communication Services 0.15%
5 Industrials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
151
CALL
Puma Biotechnology
PBYI
$399M
$2.25M 0.08%
193
+110
+133% +$19.9K
XTLB
152
XTL Biopharmaceuticals
XTLB
$6.66M
$2.21M 0.08%
57,549
-8,024
-12% -$342K
SRPT icon
153
Sarepta Therapeutics
SRPT
$1.6B
$2.18M 0.08%
71,600
+49,657
+226% +$1.02M
INFI
154
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.16M 0.08%
1,971
-678
-26% -$8.7K
OCUL icon
155
Ocular Therapeutix
OCUL
$1.83B
$2.1M 0.08%
+100,000
New +$2.48M
ALDX icon
156
Aldeyra Therapeutics
ALDX
$92.9M
$2.07M 0.08%
+266,953
New +$2.3M
CRDC
157
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$2.06M 0.08%
413,440
+27,068
+7% +$121K
RVNC
158
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.96M 0.07%
+614
New +$15.8K
HIFR
159
CALL
DELISTED
InfraREIT, Inc.
HIFR
$1.96M 0.07%
+690
New +$21.4K
RPRX
160
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$1.94M 0.07%
2,709
+768
+40% +$5.98K
HSTO
161
DELISTED
Histogen Inc. Common Stock
HSTO
$1.92M 0.07%
+1,867
New +$2.19M
HALO icon
162
PUT
Halozyme
HALO
$9.85B
$1.9M 0.07%
840
+638
+316% +$11.2K
BHC icon
163
PUT
Bausch Health
BHC
$1.67B
$1.89M 0.07%
+85
New +$18.8K
OCAT
164
DELISTED
OCATA THERAPEUTICS, INC. COMMON STOCK
OCAT
$1.86M 0.07%
+352,544
New +$2.26M
PGNX
165
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.85M 0.07%
247,706
-371,694
-60% -$2.25M
GWPH
166
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.84M 0.07%
150
+50
+50% +$5.67K
SAGE
167
DELISTED
Sage Therapeutics
SAGE
$1.83M 0.07%
+25,080
New +$1.61M
FOMX
168
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.8M 0.07%
176,000
+160,700
+1,050% +$1.78M
ACAD icon
169
PUT
Acadia Pharmaceuticals
ACAD
$4.43B
$1.8M 0.07%
+430
New +$16.6K
ENDP
170
PUT
DELISTED
Endo International plc
ENDP
$1.78M 0.07%
+224
New +$19.3K
FOLD
171
PUT
DELISTED
Amicus Therapeutics
FOLD
$1.78M 0.06%
1,257
-394
-24% -$4.74K
SCON
172
DELISTED
Superconductor Technologies Inc.
SCON
$1.78M 0.06%
1,128
+117
+12% +$198K
REE
173
DELISTED
RARE ELEMENT RES LTD
REE
$1.77M 0.06%
+4,212,092
New +$2.66M
PVCT
174
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$1.77M 0.06%
+3,275,929
New +$2.67M
CSLT
175
CALL
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.75M 0.06%
2,149
+1,065
+98% +$8.88K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2015 Portfolio in Review

As of Q2 2015, Sabby Management held 404 positions worth $2.74B, up 14% from $2.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sabby Management withdrew a net $310M in Q2 2015, closing 88 positions and reducing 80 holdings. Its most notable exit was Allergan plc, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 8.3% of assets, down from 9.4% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in ExxonMobil worth $14.8M.

  • Sabby Management's largest Q2 2015 buy was ExxonMobil: 178,310 shares worth $14.8M.
  • Sabby Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2015, an estimated $23.4M increase.
  • Sabby Management's biggest Q2 2015 reduction was Tempest Therapeutics, cutting an estimated $53.9M.
  • Sabby Management fully exited Allergan plc in Q2 2015, selling an estimated $33.8M.
  • Sabby Management's ten largest holdings make up 45% of its $2.74B portfolio in Q2 2015.
  • Sabby Management opened 120 new positions and closed 88 in Q2 2015.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $2.74B.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.